Receptor protein tyrosine phosphatases (RPTPs) are involved in a broad list of cellular, developmental, and physiological functions. Altering their expression leads to significant changes in protein phosphorylation linked to a growing list of human diseases, including cancers and neurological disorders. In this issue of Genes & Development, Qian and colleagues (pp. 743–759) present the identification of a monoclonal antibody targeting PTPRD extracellular domain-inducing dimerization and inhibition of the phosphatase activities, causing the proteolysis of dimeric PTPRD by a mechanism involving intracellular degradation pathways. Their study supports the potential of modulating PTPRD via its extracellular domains. This opens a new framework in the clinical manipulation of PTPRD and its closely related family members.

中文翻译：

---

利用抗体诱导的受体酪氨酸磷酸酶二聚化推进治疗

受体蛋白酪氨酸磷酸酶 (RPTP) 涉及广泛的细胞、发育和生理功能。改变它们的表达会导致蛋白质磷酸化发生显着变化，这些变化与越来越多的人类疾病有关，包括癌症和神经系统疾病。在本期《Genes & Development》中，Qian 及其同事（第 743-759 页）鉴定了一种针对 PTPRD 胞外结构域的单克隆抗体，可诱导二聚化并抑制磷酸酶活性，通过涉及细胞内的机制引起二聚体 PTPRD 的蛋白水解。降解途径。他们的研究支持通过其细胞外结构域调节 PTPRD 的潜力。这为 PTPRD 及其密切相关的家族成员的临床操作开辟了新的框架。